Gelesis Holdings, Inc. (GLSHQ)

Market Cap	73.00
Revenue (ttm)	12.14M -45.8%
Net Income	-51.67M
EPS	-0.71
Shares Out	73.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	0.000001
Previous Close	0.000001
Day's Range	0.000001 - 0.000001
52-Week Range	0.000001 - 0.0001
Beta	3,369.52
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Gelesis Holdings

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporate...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 93
• Stock Exchange: OTCMKTS
• Ticker Symbol: GLSHQ

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 21, 2026

Data Sources Report a data error